This is a summary of the European public assessment report (EPAR) for Stalevo. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Stalevo.
Therapeutic Indication
### Therapeutic indication Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.
Therapeutic Area (MeSH)
ATC Code
N04BA03
ATC Item
levodopa, decarboxylase inhibitor and COMT inhibitor
Pharmacotherapeutic Group
Anti-Parkinson drugs
Active Substance (Summary)
INN / Common Names
EMA Name
Stalevo
Medicine Name
Stalevo
Aliases
N/ANo risk management plan link.
